A challenge in the development of dry powder formulations for inhalation is the poor
reproducibility of their administration to small laboratory animals. The currently used devices …

To evaluate powder formulations for pulmonary administration in pre-clinic research, the
powder should be administered to the lungs of small laboratory animals. To do so properly …

Purpose: This research describes a novel “minitower” dry powder delivery system for nose-
only delivery of dry powder aerosols to spontaneously breathing rats. Methods: The …

Aerosols are an effective method to deliver therapeutic agents to the respiratory tract. Among
aerosol generation systems, dry powder inhales have been attractive area of research for …

Development of new therapeutic products requires efficacy testing in an animal model. The
pulmonary route of administration can be utilized to deliver drugs locally and systemically …

The efficacy of pharmaceutical aerosols relates to its deposition in the clinically relevant
regions of the lungs, which can be assessed by in vivo lung deposition studies. Dry powder …

Significant progress has been made over the last half-century in delivering therapeutics by
the pulmonary route. Inhaled therapeutics are administered to humans using metered-dose …

In the last decades, dry powder inhalation has become a very attractive option for pulmonary
drug delivery to treat lung diseases like cystic fibroses and lung infections. In contrast to the …

Dry powder inhalers (DPIs) are a widely accepted inhaled delivery dosage form, particularly
in Europe, where they currently are used by a large number of patients for the delivery of …

The use of orally inhaled dry powder technologies is one way of delivering medicines to the
lung for treating local conditions or for achieving systemic effect. These involve dry powder …